<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04861467</url>
  </required_header>
  <id_info>
    <org_study_id>CATCH</org_study_id>
    <nct_id>NCT04861467</nct_id>
  </id_info>
  <brief_title>Camrelizumab as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>A Randomized, Open Study of Camrelizumab vs Placebo as a Maintenance Therapy After Chemoradiation in Patients With Locally Advanced Head and Neck Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chinese Academy of Medical Sciences</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chinese Academy of Medical Sciences</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to evaluate the efficacy and safety of Camrelizumab as&#xD;
      maintenance therapy in newly diagnosed locally advanced head and neck squamous cell carcinoma&#xD;
      subjects after chemoradiation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2021</start_date>
  <completion_date type="Anticipated">December 31, 2025</completion_date>
  <primary_completion_date type="Anticipated">July 31, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>median progression-free survival(in accordance with RECIST1.1)</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>mPFS is the median time from the date of randomization to the date of first record of disease progression or death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>1 year progression-free survival rate</measure>
    <time_frame>1 year from the the date of randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>OS is the time from randomization to death due to any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>objective response rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease control rate</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>time to progression</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>progression-free survival(in accordance with irRECIST1.1)</measure>
    <time_frame>Up to 3 years</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>event-free survival in exploration group</measure>
    <time_frame>Up to 3 years</time_frame>
    <description>EFS is the time from the date of randomization to any event</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">155</enrollment>
  <condition>HNSCC</condition>
  <arm_group>
    <arm_group_label>Experimental: Camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>camrelizumab as maintenance therapy after Chemoradiation(evaluation results：PR/SD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>observation</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>observation after Chemoradiation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Exploration：Camrelizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>camrelizumab for maintenance after chemoradiation( evaluation results：CR)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Camrelizumab</intervention_name>
    <description>IV</description>
    <arm_group_label>Experimental: Camrelizumab</arm_group_label>
    <arm_group_label>Exploration：Camrelizumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Who have histologic or cytologic confirmation of head and neck squamous cell carcinoma&#xD;
             in the mouth, oropharynx (p16-), hypopharynx, or larynx.&#xD;
&#xD;
          -  Local advanced head and neck squamous cell carcinoma diagnosed as stage III-IVa by&#xD;
             AJCC 8&#xD;
&#xD;
          -  Except for the prescribed radical radiotherapy and chemotherapy regimen, there has&#xD;
             been no previous treatment for LA-HNSCC systemic antitumor or local radical therapy&#xD;
             (allowing the prescribed induction chemotherapy regimen before radical radiotherapy&#xD;
             and chemotherapy)&#xD;
&#xD;
          -  28 days after radical radiotherapy and chemotherapy (radiotherapy and chemotherapy (±7&#xD;
             days) did not show disease progression, and consideration was given within 28 days&#xD;
             after curative effect evaluation&#xD;
&#xD;
          -  Clinically assessable lesions according to RECIST1.1,(lesion length ≥10 mm or lymph&#xD;
             node short diameter ≥15 mm)&#xD;
&#xD;
          -  The age at which informed consent is signed is 18-70 years, male and female&#xD;
&#xD;
          -  KPS score ≥80 percent&#xD;
&#xD;
          -  Estimated lifetime ≥6 months&#xD;
&#xD;
          -  The function of important organs meets the following requirements (excluding the use&#xD;
             of any blood components and cytokines within 14 days):&#xD;
&#xD;
        Normal bone marrow reserve function: WBC≥3.0×10^9/ L, NEUT≥1.5×10^9/ L, PLT≥80×10^9/ L,&#xD;
        Hb≥90g/L Normal renal function or SCr≤1.5 times normal upper limit (ULN) or Ccr≥50 ml/min ;&#xD;
        Normal liver function or TBIL≤1.5 times the upper limit of normal value (ULN); AST or ALT&#xD;
        level 2.5 times the upper limit of normal value (ULN);&#xD;
&#xD;
          -  Ability and willingness to follow research and follow-up procedures&#xD;
&#xD;
          -  Men and women of childbearing age must agree to adequate contraception throughout the&#xD;
             study period and within 6 months after treatment&#xD;
&#xD;
          -  The subjects volunteered to join the clinical study and signed informed consent, good&#xD;
             compliance and follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  1.Have received any systemic anti-tumor therapy against the target lesion&#xD;
&#xD;
          -  Previous experience in head and neck radiotherapy&#xD;
&#xD;
          -  Previous immunotherapies including anti PD-1/PD-L1, anti CTLA-4, etc&#xD;
&#xD;
          -  Subjects who received anti-tumor vaccines or other immunomodulatory drugs (e.g.&#xD;
             interleukin-2, thymosin, Lentinus edodes polysaccharide, etc.) within 1 month prior to&#xD;
             joining the group, or who received live attenuated vaccines&#xD;
&#xD;
          -  Subjects who had been systematically treated with corticosteroids (prednisone or other&#xD;
             equivalent hormones &gt;10 mg/ days) or other immunosuppressants within 1 month of entry.&#xD;
             To allow inhaled or local use of corticosteroids in the absence of active autoimmune&#xD;
             disease, as well as adrenocorticotropic replacement therapy ≤10 days mg/ dose of&#xD;
             prednisone&#xD;
&#xD;
          -  Pleural effusions, pericardial effusions or ascites requiring drainage, or serosal&#xD;
             effusions for treatment within 2 weeks prior to group entry&#xD;
&#xD;
          -  No active autoimmune disease or history of autoimmune disease (including but not&#xD;
             limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis,&#xD;
             pituitary, vasculitis, nephritis, hyperthyroidism, hypothyroidism) may be included&#xD;
&#xD;
          -  Subjects with severe infection within 1 month prior to admission, including, but not&#xD;
             limited to, infection complications requiring hospitalization, bacteremia, severe&#xD;
             pneumonia, etc. Subjects with any active infection, or unexplained fever &gt;38.5℃ during&#xD;
             screening, prior to first administration&#xD;
&#xD;
          -  Severe cardiovascular disease: grade II myocardial ischemia or myocardial infarction,&#xD;
             uncontrolled arrhythmia; grade III ~ IV cardiac insufficiency, or echocardiography&#xD;
             indicated that left ventricular ejection fraction (LVEF)&lt;50%;&#xD;
&#xD;
          -  The subjects were treated with bronchiectasis and other systemic treatments. Asthma&#xD;
             control was unsatisfactory and could not be included (asthma was completely alleviated&#xD;
             in childhood and included without any intervention in adults)&#xD;
&#xD;
          -  HIV infection or known AIDS, active hepatitis B (HBV DNA≥500 IU/ml), hepatitis C&#xD;
             (hepatitis C antibody positive, and HCV-RNA higher than the lower detection limit of&#xD;
             the analytical method) or combined with hepatitis B and hepatitis C infection;&#xD;
&#xD;
          -  Subjects with a history of other malignancies within five years (except complete&#xD;
             treatment of skin cancer with cervical or basal cell carcinoma or squamous cell&#xD;
             carcinoma in situ)&#xD;
&#xD;
          -  Patients with a clear history of allergies may be allergic to, or intolerant to&#xD;
             Camrelizumab&#xD;
&#xD;
          -  Persons with a history of substance abuse and who are unable to abstain or who have&#xD;
             mental disorders Increasing the risk associated with participating in a study or&#xD;
             research drug and, according to the researcher's judgment, other circumstances in&#xD;
             which the subjects are not suitable for inclusion in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junlin Yi</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Junlin Yi</last_name>
    <phone>13661217998</phone>
    <email>yijunlin1969@163.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ye Zhang</last_name>
    <phone>010-87787625</phone>
    <email>drzye1983@163.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Cancer hospital, Chineses Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Junlin Yi, M.D.</last_name>
      <phone>13661217998</phone>
      <email>yijunlin1969@163.com</email>
    </contact>
    <investigator>
      <last_name>Junlin Yi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>April 22, 2021</study_first_submitted>
  <study_first_submitted_qc>April 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">April 27, 2021</study_first_posted>
  <last_update_submitted>April 25, 2021</last_update_submitted>
  <last_update_submitted_qc>April 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Chinese Academy of Medical Sciences</investigator_affiliation>
    <investigator_full_name>Jun-Lin Yi, MD</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Immunotherapy</keyword>
  <keyword>Chemoradiation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

